-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...
BOSTON--(BUSINESS WIRE)--Strand Therapeutics, the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient ...
An impressive array of Big Pharma backers lined up to ensure Strand Therapeutics has the funding needed to take its mRNA-based solid tumor drug further into the clinic. New Strand supporters that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback